QbD Based Method Development on an Agilent 1290 Infinity UHPLC System Combined with a Seamless Method Transfer to HPLC Using Intelligent System Emulation Technology
Applications | 2015 | Agilent TechnologiesInstrumentation
The adoption of Quality by Design (QbD) in chromatographic method development ensures robust, efficient, and transferable analytical procedures critical for pharmaceutical QA/QC. Integrating automated screening, statistical design, and system emulation addresses the challenges of moving high-throughput UHPLC methods to widely used HPLC platforms while maintaining performance and regulatory compliance.
This work aimed to develop a stability-indicating UHPLC method on an Agilent 1290 Infinity system using sub-2 µm columns under QbD principles, establish a design space, and seamlessly transfer the method to an Agilent 1260 Infinity HPLC system via Intelligent System Emulation Technology (ISET) and Agilent Method Translator. Performance and robustness were verified through DOE-based optimization and replicate testing.
A six-column, multi-factor screening employed the Agilent 1290 Infinity with automated chemistry screening (Fusion QbD and OpenLAB CDS) under varied eluents (ACN, MeOH), pH, temperature, gradient slopes, and flow rates. The best sub-2 µm C8 chemistry was optimized by a DOE to define the ICH design space. The Agilent Method Translator generated HPLC conditions (scaled column dimensions, flow, injection volume). ISET emulated a 1260 Infinity HPLC on the 1290 UHPLC, enabling DOE-based refinement of HPLC parameters. Final verification used a native Agilent 1260 Infinity system.
Initial UHPLC screening achieved rapid separation (10 min gradient) on 3 × 50 mm, 1.8 µm C8 column at pH 7.0. DOE optimization set CMPs (pH 7.7 ±0.1, 45 °C ±4 °C, 90.5 % MeOH ±1.5 %, 15 min gradient) with CMAs: ≥40 peaks, API resolution >1.5, tailing <1.5, purity ≥98 %. HPLC transfer produced a 4.6 × 150 mm, 3.5 µm C8 method (45 °C, 1.4 mL/min, 45 min gradient). DOE-enabled HPLC design space expanded compared to UHPLC, allowing API resolution >4.0 and tailing <1.3. PAR verification at corner and center points confirmed stable retention times, resolution, and peak shapes. Replicate runs on the emulated and native 1260 systems showed RSDs ≤2 % for area, RT, and resolution, with deviation between systems well within acceptance criteria.
Emerging trends involve deeper integration of machine-learning in DOE, real-time PAT feedback loops, and broader adoption of system emulation for instrument-agnostic method exchange. Expansion to other modalities (e.g., LC-MS) and on-line degradation studies could further streamline stability-indicating method development.
This study demonstrates an efficient, QbD-aligned workflow combining UHPLC screening, DOE optimization, ISET emulation, and Method Translator software to develop and transfer a robust, high-performance chromatographic method from UHPLC to HPLC. The approach yields expanded design spaces, reproducible performance on routine HPLC systems, and substantial time and resource savings.
HPLC
IndustriesPharma & Biopharma
ManufacturerAgilent Technologies
Summary
Importance of the Topic
The adoption of Quality by Design (QbD) in chromatographic method development ensures robust, efficient, and transferable analytical procedures critical for pharmaceutical QA/QC. Integrating automated screening, statistical design, and system emulation addresses the challenges of moving high-throughput UHPLC methods to widely used HPLC platforms while maintaining performance and regulatory compliance.
Study Objectives and Overview
This work aimed to develop a stability-indicating UHPLC method on an Agilent 1290 Infinity system using sub-2 µm columns under QbD principles, establish a design space, and seamlessly transfer the method to an Agilent 1260 Infinity HPLC system via Intelligent System Emulation Technology (ISET) and Agilent Method Translator. Performance and robustness were verified through DOE-based optimization and replicate testing.
Methodology and Instrumentation
A six-column, multi-factor screening employed the Agilent 1290 Infinity with automated chemistry screening (Fusion QbD and OpenLAB CDS) under varied eluents (ACN, MeOH), pH, temperature, gradient slopes, and flow rates. The best sub-2 µm C8 chemistry was optimized by a DOE to define the ICH design space. The Agilent Method Translator generated HPLC conditions (scaled column dimensions, flow, injection volume). ISET emulated a 1260 Infinity HPLC on the 1290 UHPLC, enabling DOE-based refinement of HPLC parameters. Final verification used a native Agilent 1260 Infinity system.
Main Results and Discussion
Initial UHPLC screening achieved rapid separation (10 min gradient) on 3 × 50 mm, 1.8 µm C8 column at pH 7.0. DOE optimization set CMPs (pH 7.7 ±0.1, 45 °C ±4 °C, 90.5 % MeOH ±1.5 %, 15 min gradient) with CMAs: ≥40 peaks, API resolution >1.5, tailing <1.5, purity ≥98 %. HPLC transfer produced a 4.6 × 150 mm, 3.5 µm C8 method (45 °C, 1.4 mL/min, 45 min gradient). DOE-enabled HPLC design space expanded compared to UHPLC, allowing API resolution >4.0 and tailing <1.3. PAR verification at corner and center points confirmed stable retention times, resolution, and peak shapes. Replicate runs on the emulated and native 1260 systems showed RSDs ≤2 % for area, RT, and resolution, with deviation between systems well within acceptance criteria.
Benefits and Practical Applications
- Significant time savings (19 h) and solvent reduction by using sub-2 µm columns for screening.
- Robust design spaces guarantee consistent performance across variable conditions.
- Seamless emulation and translation accelerate method transfer to routine HPLC systems common in QA/QC labs.
- Automated workflows reduce manual adjustments, supporting cGMP compliance.
Future Trends and Potential Applications
Emerging trends involve deeper integration of machine-learning in DOE, real-time PAT feedback loops, and broader adoption of system emulation for instrument-agnostic method exchange. Expansion to other modalities (e.g., LC-MS) and on-line degradation studies could further streamline stability-indicating method development.
Conclusion
This study demonstrates an efficient, QbD-aligned workflow combining UHPLC screening, DOE optimization, ISET emulation, and Method Translator software to develop and transfer a robust, high-performance chromatographic method from UHPLC to HPLC. The approach yields expanded design spaces, reproducible performance on routine HPLC systems, and substantial time and resource savings.
References
- Vinayak A. K.; Syed Lateef. Automated QbD-Based Method Development and Validation of Oxidative Degraded Atorvastatin. Agilent Technologies 5991-4944EN, 2014.
- Huesgen A. G. Fast screening of mobile and stationary phases with the Agilent 1290 Infinity LC and seamless method transfer to an Agilent 1200 Series LC using ISET. Agilent Technologies 5991-0989EN, 2012.
- Syed Lateef, Vinayak A. K. Stability Indicating Method Development for Linagliptin Drug Product using Quality-by-Design. Agilent Technologies 5591-3834EN, 2014.
- Huesgen A. G. Agilent 1290 Infinity Binary LC with ISET – Emulation of the Waters Alliance 2695 LC System Analyzing Analgesics. Agilent Technologies 5991-2792EN, 2013.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Quality-by-Design-Based Method Development Using an Agilent 1290 Infinity II LC
2017|Agilent Technologies|Applications
Quality-by-Design-Based Method Development Using an Agilent 1290 Infinity II LC An Efficient Method Development Workflow Combined with ISET-mediated Method Transfer Under Waters Empower 3 CDS Control Application Note Pharmaceutical Developments and QA/QC Authors Abstract Vinayak A.K and Andreas Tei This…
Key words
imp, impqbd, qbdmethod, methodiset, isetuhplc, uhplcapi, apimin, minemulation, emulationzorbax, zorbaximpurity, impurityamlodipine, amlodipinehplc, hplctime, timefusion, fusionagilent
AGILENT SOLUTIONS FOR QUALITY-BY-DESIGN IMPLEMENTATION IN PHARMACEUTICAL DEVELOPMENT
2014|Agilent Technologies|Guides
GAIN GREATER CONFIDENCE AGILENT SOLUTIONS FOR QUALITY-BY-DESIGN IMPLEMENTATION IN PHARMACEUTICAL DEVELOPMENT Primer CONTENTS INTRODUCTION: AN OVERVIEW OF QUALITY BY DESIGN......................................................................................3 ELIMINATING VARIABILITY IN ANALYTICAL METHOD DEVELOPMENT...........................................................................5 Automated Method Development Solution with Multivariate Analysis for Evaluation of Design Space...................................................................................................... 7 Instrument…
Key words
qbd, qbdmethod, methoddevelopment, developmentdissolution, dissolutionquality, qualitydesign, designcritical, criticalanalytical, analyticalagilent, agilentattributes, attributesiset, isetprinciples, principlesrisk, riskvariability, variabilityimpurity
Quality‑by‑Design Approach to Stability Indicating Method Development for Linagliptin Drug Product
2014|Agilent Technologies|Applications
Quality-by-Design Approach to Stability Indicating Method Development for Linagliptin Drug Product Application Note Pharmaceutical QA/QC Authors Abstract Syed Salman Lateef and Vinayak AK A traditional approach to method development could fail to meet desired Agilent Technologies, Inc. separation during validation,…
Key words
method, methodvariables, variablesfusion, fusionlinagliptin, linagliptinqbd, qbddesign, designdevelopment, developmentdoe, doegradient, gradientphase, phasemodeled, modeledparameters, parametersindicating, indicatingapi, apiquality
Peptide Mapping: A Quality by Design (QbD) Approach
2017|Agilent Technologies|Applications
Peptide Mapping: A Quality by Design (QbD) Approach Application Note Bio-Pharmaceutical Authors Abstract Sreelakshmy Menon and Peptide mapping is a widely used technique for the characterization of proteins. Suresh babu C.V. This Application Note demonstrates a robust LC method and…
Key words
qbd, qbddesign, designmethod, methodtangent, tangentdoe, doepeptide, peptidemapping, mappinghold, holdcmas, cmasspace, spaceintermediate, intermediateexperiment, experimentoven, ovendevelopment, developmentfinal